Top

International Urology and Nephrology

Published in:

01-03-2019 | Prostate Cancer | Urology - Original Paper

SAMD5 mRNA was overexpressed in prostate cancer and can predict biochemical recurrence after radical prostatectomy

Authors: Fei Li, Yong Xu, Ran-Lu Liu

Published in: International Urology and Nephrology | Issue 3/2019

Abstract

Purpose

To identify a novel biomarker that can predict biochemical recurrence (BCR) after radical prostatectomy.

Methods

The gene expression profile of SAMD5 in prostate cancer was explored based on the oncomine database and The Cancer Genomic Atlas (TCGA). The follow-up information and clinical pathologic variables were extracted from the following cohort study: TCGA_prostate carcinoma. And then, survival analysis was conducted using the Kaplan–Meier plot and Cox’s proportional hazard regression model. Furthermore, another independent cohort study: Taylor prostate, was also acquired to validate the predictive effect of SAMD5 on BCR. In addition, the expression profile of SAMD5 in other cancer types was investigated using TCGA dataset.

Results

SAMD5 mRNA was shown to be up-regulated in multiple microarray datasets of prostate cancer with the strict statistic criteria: p < 0.01 and fold change ≥ 2. In TCGA_PCa cohort study, high expression of SAMD5 was a risk factor for patients on post-operative BCR (HR 2.181, 95%CI 1.199–3.966, p = 0.011) and this predictive ability was independent of Gleason score and pathologic T stage (HR 2.018, 95%CI 1.102–3.698, p = 0.023). In another validating cohort study, the statistic trend was similar, and the pooled analysis by combining the two cohort study further confirmed its prognostic effect.

Conclusion

SAMD5 mRNA was overexpressed in prostate cancer and had powerful prognostic ability on predicting post-operative BCR, independent of Gleason score and pathologic T stage. Its high expression was associated with poor prognosis after RP.

Available only for authorised users

Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492 CrossRefPubMed

Cornford P, Bellmunt J, Bolla M et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 71:630–642. https://doi.org/10.1016/j.eururo.2016.08.002 CrossRefPubMed

Li D, Lv H, Hao X et al (2018) Prognostic value of serum alkaline phosphatase in the survival of prostate cancer: evidence from a meta-analysis. Cancer Manage Res 10:3125–3139. https://doi.org/10.2147/CMAR.S174237 CrossRef

Uhlen M, Zhang C, Lee S et al (2017) A pathology atlas of the human cancer transcriptome. Science. https://doi.org/10.1126/science.1260419 CrossRefPubMed

Wang Y, Shang Y, Li J et al (2018) Specific Eph receptor-cytoplasmic effector signaling mediated by SAM-SAM domain interactions. elife. https://doi.org/10.7554/eLife.35677 CrossRefPubMedPubMedCentral

Matsuo T, Dat le T, Komatsu M et al (2014) Early growth response 4 is involved in cell proliferation of small cell lung cancer through transcriptional activation of its downstream genes. PLoS ONE 9:e113606. https://doi.org/10.1371/journal.pone.0113606 CrossRefPubMedPubMedCentral

Watanabe T, Kobunai T, Akiyoshi T et al (2014) Prediction of response to preoperative chemoradiotherapy in rectal cancer by using reverse transcriptase polymerase chain reaction analysis of four genes. Dis Colon Rectum 57:23–31. https://doi.org/10.1097/01.dcr.0000437688.33795.9d CrossRefPubMed

The Cancer Genome Atlas Research Network (2015) The molecular taxonomy of primary prostate cancer. Cell 163:1011–1025. https://doi.org/10.1016/j.cell.2015.10.025 CrossRefPubMedCentral

Taylor BS, Schultz N, Hieronymus H et al (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18:11–22. https://doi.org/10.1016/j.ccr.2010.05.026 CrossRefPubMedPubMedCentral

10.

Rhodes DR, Yu J, Shanker K et al (2004) ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6:1–6. https://doi.org/10.1016/S1476-5586(04)80047-2 CrossRefPubMedPubMedCentral

11.

Tang Z, Li C, Kang B et al (2017) GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res 45:W98–W102. https://doi.org/10.1093/nar/gkx247 CrossRefPubMedPubMedCentral

12.

Li B, Ruotti V, Stewart RM et al (2010) RNA-Seq gene expression estimation with read mapping uncertainty. Bioinformatics 26:493–500. https://doi.org/10.1093/bioinformatics/btp692 CrossRefPubMed

13.

Thompson IM, Andriole GL, Blumenstein B et al (2003) AJCC cancer staging manual, 6th edn. Springer, New York

14.

Cerami E, Gao J, Dogrusoz U et al (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401–404. https://doi.org/10.1158/2159-8290.CD-12-0095 CrossRefPubMed

15.

Gao J, Aksoy BA, Dogrusoz U et al (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6:pl1. https://doi.org/10.1126/scisignal.2004088 CrossRefPubMedPubMedCentral

16.

Tripathi S, Pohl MO, Zhou Y et al (2015) Meta- and Orthogonal integration of influenza “OMICs” data defines a role for UBR4 in virus budding. Cell Host Microbe 18:723–735. https://doi.org/10.1016/j.chom.2015.11.002 CrossRefPubMedPubMedCentral

17.

Tomlins SA, Mehra R, Rhodes DR et al (2007) Integrative molecular concept modeling of prostate cancer progression. Nat Genet 39:41–51. https://doi.org/10.1038/ng1935 CrossRefPubMed

18.

Varambally S, Yu J, Laxman B et al (2005) Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8:393–406. https://doi.org/10.1016/j.ccr.2005.10.001 CrossRefPubMed

19.

Lapointe J, Li C, Higgins JP et al (2004) Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 101:811–816. https://doi.org/10.1073/pnas.0304146101 CrossRefPubMedPubMedCentral

20.

Arredouani MS1, Lu B, Bhasin M et al (2009) Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer. Clin Cancer Res 15:5794–5802. https://doi.org/10.1158/1078-0432.CCR-09-0911 CrossRefPubMedPubMedCentral

21.

Grasso CS, Wu YM, Robinson DR et al (2012) The mutational landscape of lethal castration-resistant prostate cancer. Nature 487:239–243. https://doi.org/10.1038/nature11125 CrossRefPubMedPubMedCentral

22.

Luo JH, Yu YP, Cieply K et al (2002) Gene expression analysis of prostate cancers. Mol Carcinog 33:25–35. https://doi.org/10.1002/mc.10018 CrossRefPubMed

23.

Yagai T, Matsui S, Harada K et al (2017) Expression and localization of sterile alpha motif domain containing 5 is associated with cell type and malignancy of biliary tree. PLoS ONE 12:e0175355. https://doi.org/10.1371/journal.pone.0175355 CrossRefPubMedPubMedCentral

24.

Lemmon MA, Schlessinger J (2010) Cell signaling by receptor tyrosine kinases. Cell 141:1117–1134. https://doi.org/10.1016/j.cell.2010.06.011 CrossRefPubMedPubMedCentral

Title: SAMD5 mRNA was overexpressed in prostate cancer and can predict biochemical recurrence after radical prostatectomy
Authors: Fei Li
Yong Xu
Ran-Lu Liu
Publication date: 01-03-2019
Publisher: Springer Netherlands
Keywords: Prostate Cancer
Prostate Cancer
Prostatectomy
Prostatectomy
Biomarkers
Published in: International Urology and Nephrology / Issue 3/2019
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-019-02096-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2019

Association of the blood urea nitrogen-to-left ventricular ejection fraction ratio with contrast-induced nephropathy in patients with acute coronary syndrome who underwent percutaneous coronary intervention

Whole mount histopathological correlation with prostate MRI in Grade I and II prostatectomy patients

Relationship between cFGF23/Klotho ratio and phosphate levels in patients with chronic kidney disease

Peritoneal dialysis can alleviate the clinical course of hungry bone syndrome after parathyroidectomy in dialysis patients with secondary hyperparathyroidism

Organ-sparing procedures in GU cancer: part 1—organ-sparing procedures in renal and adrenal tumors: a systematic review

Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials